Published in J Biol Chem on January 24, 2007
Receptors of anthrax toxin and cell entry. Mol Aspects Med (2009) 1.18
Anthrax toxin receptor 2 determinants that dictate the pH threshold of toxin pore formation. PLoS One (2007) 1.16
Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin. Proc Natl Acad Sci U S A (2010) 1.11
Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy. Front Biosci (Landmark Ed) (2011) 1.10
The cell surface structure of tumor endothelial marker 8 (TEM8) is regulated by the actin cytoskeleton. Biochim Biophys Acta (2010) 1.01
Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death. Bioorg Med Chem (2009) 0.95
Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates. Vaccine (2007) 0.92
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Mol Cancer Ther (2008) 0.91
Selective blockade of tumor angiogenesis. Cell Cycle (2012) 0.91
The structure of tumor endothelial marker 8 (TEM8) extracellular domain and implications for its receptor function for recognizing anthrax toxin. PLoS One (2010) 0.89
Imaging tumor endothelial marker 8 using an 18F-labeled peptide. Eur J Nucl Med Mol Imaging (2011) 0.84
New radiotracers for imaging of vascular targets in angiogenesis-related diseases. Adv Drug Deliv Rev (2014) 0.83
Contributions of edema factor and protective antigen to the induction of protective immunity by Bacillus anthracis edema toxin as an intranasal adjuvant. J Immunol (2010) 0.81
Tumor Targeting and Drug Delivery by Anthrax Toxin. Toxins (Basel) (2016) 0.80
Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden. Oncotarget (2015) 0.79
The Ins and Outs of Anthrax Toxin. Toxins (Basel) (2016) 0.77
The case for developing consensus standards for research in microbial pathogenesis: Bacillus anthracis toxins as an example. Infect Immun (2009) 0.77
Effective delivery of antisense peptide nucleic acid oligomers into cells by anthrax protective antigen. Biochem Biophys Res Commun (2008) 0.76
Anthrax Toxin Protective Antigen Variants That Selectively Utilize either the CMG2 or TEM8 Receptors for Cellular Uptake and Tumor Targeting. J Biol Chem (2016) 0.75
Crystallization and preliminary X-ray analysis of the vWA domain of human anthrax toxin receptor 1. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 0.75
Capillary morphogenesis gene 2 inhibits growth of breast cancer cells and is inversely correlated with the disease progression and prognosis. J Cancer Res Clin Oncol (2014) 0.75
Genes expressed in human tumor endothelium. Science (2000) 10.75
Identification of the cellular receptor for anthrax toxin. Nature (2001) 8.78
Crystal structure of the anthrax toxin protective antigen. Nature (1997) 6.63
Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci U S A (2003) 5.95
Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci U S A (1992) 4.91
Crystal structure of the anthrax lethal factor. Nature (2001) 3.75
Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature (2002) 3.67
Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature (2004) 3.36
Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res (2001) 3.29
An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. J Mol Biol (1996) 3.15
Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation. Proc Natl Acad Sci U S A (2004) 3.10
Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J Biol Chem (2002) 2.76
A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo. J Biol Chem (1989) 2.31
Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J Biol Chem (1993) 2.23
Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem (2003) 2.19
TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res (2004) 2.07
Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor. Proc Natl Acad Sci U S A (2004) 1.91
Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis. J Ind Microbiol Biotechnol (2002) 1.75
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem (2001) 1.73
Crystal structure of the I domain from integrin alpha2beta1. J Biol Chem (1997) 1.69
Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect Immun (1999) 1.68
Anthrax toxin: the long and winding road that leads to the kill. Trends Microbiol (2005) 1.68
A soluble receptor decoy protects rats against anthrax lethal toxin challenge. J Infect Dis (2005) 1.54
Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res (2000) 1.43
Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci U S A (2003) 1.38
Sequence specificities of human fibroblast and neutrophil collagenases. J Biol Chem (1991) 1.34
Anthrax toxin receptor 2-dependent lethal toxin killing in vivo. PLoS Pathog (2006) 1.34
Anthrax toxin: structures, functions and tumour targeting. Expert Opin Biol Ther (2003) 1.32
Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin. Nat Biotechnol (2005) 1.17
Optimal subsite occupancy and design of a selective inhibitor of urokinase. J Biol Chem (1997) 1.14
Functional analysis of the carboxy-terminal domain of Bacillus anthracis protective antigen. Infect Immun (1999) 1.14
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol (2009) 12.13
Talin binding to integrin beta tails: a final common step in integrin activation. Science (2003) 7.56
Structural basis of integrin activation by talin. Cell (2007) 5.37
Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science (2005) 5.25
Structural determinants of integrin recognition by talin. Mol Cell (2003) 4.20
S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science (2002) 4.13
Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol (2003) 3.97
Structural basis for vinculin activation at sites of cell adhesion. Nature (2004) 3.62
Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest (2003) 3.57
The structure and regulation of vinculin. Trends Cell Biol (2006) 3.52
Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature (2004) 3.36
The phosphotyrosine binding-like domain of talin activates integrins. J Biol Chem (2002) 2.97
Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med (2009) 2.93
The roles of anthrax toxin in pathogenesis. Curr Opin Microbiol (2004) 2.89
Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc Natl Acad Sci U S A (2003) 2.89
Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature (2003) 2.83
Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol (2002) 2.77
Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J Biol Chem (2002) 2.76
Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am J Pathol (2005) 2.45
Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature (2012) 2.41
The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin. Cell (2006) 2.40
Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway. J Cell Biol (2004) 2.31
Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proc Natl Acad Sci U S A (2009) 2.22
Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem (2003) 2.19
Receptor palmitoylation and ubiquitination regulate anthrax toxin endocytosis. J Cell Biol (2006) 2.15
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis (2011) 2.12
The focal adhesion targeting (FAT) region of focal adhesion kinase is a four-helix bundle that binds paxillin. Nat Struct Biol (2002) 2.11
Anthrax lethal toxin-induced inflammasome formation and caspase-1 activation are late events dependent on ion fluxes and the proteasome. Cell Microbiol (2007) 2.09
Role of vinculin in regulating focal adhesion turnover. Eur J Cell Biol (2006) 2.03
Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis (2007) 2.01
Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am J Physiol Regul Integr Comp Physiol (2004) 1.97
Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity. Infect Immun (2004) 1.95
The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat Struct Mol Biol (2003) 1.91
Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLoS Pathog (2012) 1.90
Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc Natl Acad Sci U S A (2003) 1.87
Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol (2003) 1.86
Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Blood (2010) 1.82
Structure and lytic activity of a Bacillus anthracis prophage endolysin. J Biol Chem (2005) 1.79
Identification of the proteins required for biosynthesis of diphthamide, the target of bacterial ADP-ribosylating toxins on translation elongation factor 2. Mol Cell Biol (2004) 1.76
Cysteine regulation of protein function--as exemplified by NMDA-receptor modulation. Trends Neurosci (2002) 1.76
Genome engineering in Bacillus anthracis using Cre recombinase. Infect Immun (2006) 1.74
Spatial localization of bacteria controls coagulation of human blood by 'quorum acting'. Nat Chem Biol (2008) 1.74
Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells. Mol Cancer Ther (2004) 1.68
An antibody-based microarray assay for small RNA detection. Nucleic Acids Res (2006) 1.65
Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect Immun (2005) 1.64
Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design. Proc Natl Acad Sci U S A (2005) 1.63
Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci (2007) 1.63
Fluid support worsens outcome and negates the benefit of protective antigen-directed monoclonal antibody in a lethal toxin-infused rat Bacillus anthracis shock model. Crit Care Med (2007) 1.63
Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats. Crit Care Med (2009) 1.60
The amidation step of diphthamide biosynthesis in yeast requires DPH6, a gene identified through mining the DPH1-DPH5 interaction network. PLoS Genet (2013) 1.56
Expression of Bacillus anthracis protective antigen in transgenic chloroplasts of tobacco, a non-food/feed crop. Vaccine (2004) 1.56
Characterization of an actin-binding site within the talin FERM domain. J Mol Biol (2004) 1.55
CA-074Me protection against anthrax lethal toxin. Infect Immun (2009) 1.55
Role of N-terminal amino acids in the potency of anthrax lethal factor. PLoS One (2008) 1.54
Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem (2006) 1.53
Retroviral insertional mutagenesis identifies a small protein required for synthesis of diphthamide, the target of bacterial ADP-ribosylating toxins. Mol Cell (2003) 1.51
Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis (2004) 1.51
Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice. Cell Host Microbe (2010) 1.51
Susceptibility to anthrax lethal toxin-induced rat death is controlled by a single chromosome 10 locus that includes rNlrp1. PLoS Pathog (2010) 1.50
Characterization of the interaction between anthrax toxin and its cellular receptors. Cell Microbiol (2007) 1.49
Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci (2006) 1.45
Anthrax protective antigen cleavage and clearance from the blood of mice and rats. Infect Immun (2007) 1.45
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J Biol Chem (2007) 1.41
Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J Biol Chem (2008) 1.40
Inflammasome sensor Nlrp1b-dependent resistance to anthrax is mediated by caspase-1, IL-1 signaling and neutrophil recruitment. PLoS Pathog (2010) 1.39
Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci U S A (2003) 1.38
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage. Microb Pathog (2007) 1.36
Structural determinants of integrin binding to the talin rod. J Biol Chem (2009) 1.35
Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol (2003) 1.34
Efficient synthetic inhibitors of anthrax lethal factor. Proc Natl Acad Sci U S A (2005) 1.32
Structural basis for phosphatidylinositol phosphate kinase type Igamma binding to talin at focal adhesions. J Biol Chem (2004) 1.32
Anthrax toxins induce shock in rats by depressed cardiac ventricular function. PLoS One (2007) 1.32
Anthrax toxin: structures, functions and tumour targeting. Expert Opin Biol Ther (2003) 1.32
The heart is an early target of anthrax lethal toxin in mice: a protective role for neuronal nitric oxide synthase (nNOS). PLoS Pathog (2009) 1.30
Key tissue targets responsible for anthrax-toxin-induced lethality. Nature (2013) 1.28
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther (2005) 1.27
αE-catenin is an autoinhibited molecule that coactivates vinculin. Proc Natl Acad Sci U S A (2012) 1.25
Structural analysis of Siah1-Siah-interacting protein interactions and insights into the assembly of an E3 ligase multiprotein complex. J Biol Chem (2005) 1.23
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun (2009) 1.22
A Bacillus anthracis strain deleted for six proteases serves as an effective host for production of recombinant proteins. Protein Expr Purif (2011) 1.21
Structural basis of von Willebrand factor activation by the snake toxin botrocetin. Structure (2002) 1.21
Imaging specific cell-surface proteolytic activity in single living cells. Nat Methods (2006) 1.20
Codon-optimized fluorescent proteins designed for expression in low-GC gram-positive bacteria. Appl Environ Microbiol (2009) 1.19
Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice. Infect Immun (2006) 1.19